6533b7d6fe1ef96bd1265e2f
RESEARCH PRODUCT
Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3
Mark KudoloAhmed El-gokhaJoana T. MacedoStefan LauferPierre KochBaerbel S. BlaumFrancesco AnsideriDieter SchollmeyerCamilla ScarpelliniDhafer Saber ZinadFrank M. BoecklerMichael Eitelsubject
MAPK/ERK pathwaybiology010405 organic chemistryKinaseChemistryStereochemistryGeneral Chemical Engineeringc-junGeneral Chemistry01 natural sciencesArticle0104 chemical scienceslcsh:Chemistry010404 medicinal & biomolecular chemistrylcsh:QD1-999Mitogen-activated protein kinasebiology.proteinTransferaseSelectivityProtein kinase AIC50description
Starting from known p38α mitogen-activated protein kinase (MAPK) inhibitors, a series of inhibitors of the c-Jun N-terminal kinase (JNK) 3 was obtained. Altering the substitution pattern of the pyridinylimidazole scaffold proved to be effective in shifting the inhibitory activity from the original target p38α MAPK to the closely related JNK3. In particular, a significant improvement for JNK3 selectivity could be achieved by addressing the hydrophobic region I with a small methyl group. Furthermore, additional structural modifications permitted to explore structure–activity relationships. The most potent inhibitor 4-(4-methyl-2-(methylthio)-1H-imidazol-5-yl)-N-(4-morpholinophenyl)pyridin-2-amine showed an IC50 value for the JNK3 in the low triple digit nanomolar range and its binding mode was confirmed by X-ray crystallography.
year | journal | country | edition | language |
---|---|---|---|---|
2018-07-01 | ACS Omega |